Damora Therapeutics, Inc. is a preclinical stage biotechnology company. Its lead product candidate is DMR-001, which has not yet been administered to humans. The company acquired Pre-Acquisition Damora in November 2025 and relies on collaborations and licensing arrangements, including with Paragon, to advance its drug discovery and development programs targeting unspecified diseases.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115922 | EDGAR | 91K words |
| 2025-03-19 | 2024-12-31 | 0000950170-25-041981 | EDGAR | 98K words |
| 2024-03-08 | 2023-12-31 | 0000950170-24-028610 | EDGAR | 92K words |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006807 | EDGAR | 96K words |
| 2022-02-17 | 2021-12-31 | 0001564590-22-005569 | EDGAR | 96K words |
| 2021-03-29 | 2020-12-31 | 0001564590-21-015916 | EDGAR | 99K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001193125-26-342307 | EDGAR | 57K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269426 | EDGAR | 21K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-102963 | EDGAR | 21K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066884 | EDGAR | 19K words |
| 2024-11-01 | 2024-09-30 | 0000950170-24-119809 | EDGAR | 21K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095383 | EDGAR | 21K words |
| 2024-04-29 | 2024-03-31 | 0000950170-24-049808 | EDGAR | 18K words |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059367 | EDGAR | 24K words |
| 2023-07-31 | 2023-06-30 | 0000950170-23-035925 | EDGAR | 21K words |
| 2023-04-28 | 2023-03-31 | 0000950170-23-015461 | EDGAR | 19K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022935 | EDGAR | 20K words |
| 2022-07-29 | 2022-06-30 | 0000950170-22-013434 | EDGAR | 19K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-20 | 0001193125-26-308899 | EDGAR | 1K words |
| 2026-03-23 | 0001193125-26-118699 | EDGAR | 6K words |
| 2026-03-10 | 0001193125-26-099404 | EDGAR | 1K words |
| 2026-02-11 | 0001193125-26-046817 | EDGAR | 28K words |
| 2026-02-10 | 0001193125-26-043741 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009812 | EDGAR | 5K words |
| 2026-01-06 | 0001193125-26-003490 | EDGAR | 6K words |
| 2025-11-10 | 0001193125-25-273342 | EDGAR | 4K words |
| 2025-06-20 | 0000950170-25-088168 | EDGAR | 1K words |
| 2024-10-15 | 0000950170-24-114481 | EDGAR | 1K words |
75 total filings indexed. 47 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001800315 |
| Ticker | DMRA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.damoratx.com |
| Listed | 2020-10-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/DMRA (~200 tokens, structured JSON with cryptographic provenance)